Jennifer Su

Jennifer Su

Auto-generated profile, based on publicly available information

Jennifer Su

Massachusetts General Hospital 1 Center for Systems Biology Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CSCarina Shiau
Carina Shiau
JCJingyi Cao
Jingyi Cao
DGDennis Gong
Dennis Gong
MGMark T. Gregory
Mark T. Gregory
NCNicholas J Caldwell
Nicholas J Caldwell
WHWilliam L. Hwang
William L. Hwang

8 May 2025 in Science
Verified
Journal Article
Closed access
ZEZackery A. Ely
Zackery A. Ely
ZKZachary J. Kulstad
Zachary J. Kulstad
GGGurcan Gunaydin
Gurcan Gunaydin
SASudarsana Addepalli
Sudarsana Addepalli
EVEva K. Verzani
Eva K. Verzani
WFWilliam A. Freed-Pastor
William A. Freed-Pastor
Translation of the noncoding genome in cancer can generate cryptic (noncanonical) peptides capable of presentation by human leukocyte antigen class I (HLA-I); however, the cancer specificity and immunogenicity of noncanonical HLA-I–bound peptides (ncHLAp) are incompletely understood. Using high-resolution immunopeptidomics, we discovered that cryptic peptides are abundant in the pancreatic cancer immunopeptidome. Approximately 30% of ncHLAp exhibited cancer-restricted translation, and a substantial subset were shared among patients. Cancer-restricted ncHLAp displayed robust immunogenic potential in a sensitive ex vivo T cell priming platform. ncHLAp-reactive, T cell receptor–redirected T cells exhibited tumoricidal activity against patient-derived pancreatic cancer organoids. These findings demonstrate that pancreatic cancer harbors cancer-restricted ncHLAp that can be recognized by cytotoxic T cells. Future therapeutic strategies for pancreatic cancer, and potentially other solid tumors, may include targeting cryptic antigens.

18 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JAJeanna M. Arbesfeld-Qiu
Jeanna M. Arbesfeld-Qiu
JCJae-Won Cho
Jae-Won Cho
PNPhuong T.T. Nguyen
Phuong T.T. Nguyen
NLNicole A. Lester
Nicole A. Lester
JSJennifer Su
Jennifer Su
WHWilliam L. Hwang
William L. Hwang
Purpose: Pancreatic neuroendocrine tumors (PNET) are rare malignancies of the endocrine pancreas with diverse clinical outcomes. Whereas some PNETs are indolent, others are aggressive and metastasize quickly. However, clinically relevant molecular stratification for PNET to predict outcomes and guide therapeutic decision-making is limited. Thus, there is an urgent need to understand the molecular heterogeneity of PNETs to refine prognostication and discover novel therapeutic vulnerabilities. Experimental Design: We performed single-nucleus RNA sequencing on untreated, resected primary, and metastatic PNETs (n = 18). We inferred gene expression programs (GEP) of malignant and nonmalignant cells and investigated associations with clinical outcomes. Next, we inferred interactions in the tumor microenvironment (TME) and performed transwell migration assays for functional validation. Finally, we explored genomic and transcriptomic evolution in a unique case study of an untreated primary PNET with two asynchronous hepatic metastases. Results: A malignant GEP enriched for neural/synaptic signaling genes was associated with worse overall survival, broad chromosomal loss of heterozygosity, and alternative lengthening of telomeres. Another malignant GEP enriched for VEGF signaling increased throughout metastatic progression in our case study. We found that macrophage-derived glutamate drives polarization toward an immunosuppressive phenotype and activates the MAPK/ERK pathway in malignant cells to increase migratory capacity. Conclusions: This study provides a detailed single-nucleus transcriptomic classification of malignant, stromal, and immune cell types and states in PNETs, their interactions in the TME, and associations with clinical outcomes. The refined molecular taxonomy of PNET may guide the development of more efficacious biomarkers and therapeutic strategies.


19 June 2026
Verified
Other
Open access
JAJeanna M. Arbesfeld-Qiu
Jeanna M. Arbesfeld-Qiu
JCJae-Won Cho
Jae-Won Cho
PNPhuong T.T. Nguyen
Phuong T.T. Nguyen
NLNicole A. Lester
Nicole A. Lester
JSJennifer Su
Jennifer Su
WHWilliam L. Hwang
William L. Hwang
Supplementary Tables 1 from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors

15 November 2022 in Cancer Research
Verified
Journal Article
Open access
JGJimmy A. Guo
Jimmy A. Guo
JSJennifer Su
Jennifer Su
AJAnanya Jambhale
Ananya Jambhale
JDJulien Dilly
Julien Dilly
CHConnor J. Hennessey
Connor J. Hennessey
AAAndrew J. Aguirre
Andrew J. Aguirre
Transcriptional states in pancreatic cancer can stratify patients by response to chemotherapy and clinical outcomes. These include the classical and basal-like states as well as a newly identified neural-like progenitor (NRP) state, which we have previously found to be enriched in primary patient tumors treated with neoadjuvant chemotherapy and radiotherapy. While several transcription factor drivers of classical and basal-like identity have been described, key regulators of the NRP state are unknown. Through in silico approaches, we identified candidate transcription factors of the NRP state, including GLIS3, a Krüppel-like zinc finger protein that mediates neuroendocrine fate during pancreatic development and differentiation of human embryonic stem cells into posterior neural progenitor cells. Our understanding of biologic and clinically-relevant attributes of transcriptional cell states remains limited by state-specific biases in various preclinical models. Existing human cell lines maintained as two-dimensional cultures tend to preferentially represent the basal-like state, whereas human three-dimensional organoid models grown in standard culture conditions best reflect the classical state. These phenotypes are therefore impacted by culture conditions as well as underlying genetic features. Furthermore, most murine pancreatic cancer models do not fully reflect the classical vs. basal-like state heterogeneity observed in humans. To enable systematic study of the classical, basal-like and NRP phenotypes, we developed isogenic KP (KrasG12D/+;Trp53FL/FL) murine organoids with a germline dCas9-VPR system to enable facile overexpression of state-specific transcription factors through CRISPR activation approaches. Quantitative PCR, RNA-sequencing, and proteomics confirmed Gata6, deltaN Trp63, and Glis3 as drivers of classical, basal-like, and NRP identity, respectively. DeltaN Trp63 organoids were further differentiated by loss of luminal morphology. Pairwise comparisons of global transcriptional alterations suggest the greatest similarities between the Gata6- and Glis3-overexpressed models, which is consistent with enhanced associations between classical and NRP states in patient tumors. Finally, although basal-like and NRP states are associated with poorer response to multi-agent chemotherapy, state-specific therapeutic sensitivities to other treatments remain incompletely defined. We therefore performed drug sensitivity assays with a panel of targeted therapies and unveiled state-specific sensitivities. These data were corroborated by drug sensitivity profiling of human patient-derived organoids and cell lines. Taken together, these results suggest a framework for defining cell state-specific vulnerabilities that may aid in stratifying and treating pancreatic cancer patients with new therapies. Citation Format: Jimmy A. Guo, Jennifer Su, Ananya Jambhale, Julien Dilly, Connor J. Hennessey, Carina Shiau, Patrick Yu, Steven Wang, Junning Wang, Laleh Abbassi, James Neiswender, Tate Bertea, Annan Yang, Qijia Yu, Peter Westcott, Jason Schenkel, Daniel Y. Kim, Hannah I. Hoffman, Grissel Cervantes Jaramillo, Giselle A. Uribe, Westley W. Wu, Arnav Mehta, David Ting, Julian A. Pacheco, Amy Deik, Clary Clish, Francisca Vazquez, Brian Wolpin, Aviv Regev, William A. Freed-Pastor, Joseph D. Mancias, Tyler Jacks, William L. Hwang, Andrew J. Aguirre. Systematic dissection of transcriptional states in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A052.